Exploring innate glycopeptide resistance mechanisms in Staphylococcus aureus

Trends in Microbiology

Volumn 18, Issue 2, 2010, Pages 55-56

  Renzoni, Adriana ^a   Kelley, William L ^a   Vaudaux, Pierre ^a   Cheung, Ambrose L ^b   Lew, Daniel P ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; BETA LACTAM ANTIBIOTIC; DAPTOMYCIN; METICILLIN; PENICILLIN BINDING PROTEIN; POLYMYXIN B; POLYPEPTIDE ANTIBIOTIC AGENT; TEICOPLANIN; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIAL MEMBRANE; BACTERIAL STRAIN; BACTERIUM ISOLATION; DRUG PROTEIN BINDING; DRUG TARGETING; GENE EXPRESSION; LETTER; NONHUMAN; OPEN READING FRAME; PHENOTYPE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; STAPHYLOCOCCUS AUREUS;

ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, BACTERIAL; GLYCOPEPTIDES; HUMANS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS;

STAPHYLOCOCCUS AUREUS;

EID: 75449083066     PISSN: 0966842X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tim.2009.11.005     Document Type: Letter

References (15)

1. Tenover F.C., and Moellering Jr. R.C. The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus. Clin. Infect. Dis. 44 (2007) 1208-1215
2. Hiramatsu K. Vancomycin-resistant Staphylococcus aureus: a new model of antibiotic resistance. Lancet Infect. Dis. 1 (2001) 147-155
3. Allen N.E., and Nicas T.I. Mechanism of action of oritavancin and related glycopeptide antibiotics. FEMS Microbiol. Rev. 26 (2003) 511-532
4. Cui L., et al. Cell wall thickening is a common feature of vancomycin resistance in Staphylococcus aureus. J. Clin. Microbiol. 41 (2003) 5-14
5. Bischoff M., and Berger-Bächi B. Teicoplanin stress-selected mutations increasing sigma(B) activity in Staphylococcus aureus. Antimicrob. Agents Chemother. 45 (2001) 1714-1720
6. Kuroda M., et al. Two-component system VraSR positively modulates the regulation of cell-wall biosynthesis pathway in Staphylococcus aureus. Mol. Microbiol. 49 (2003) 807-821
7. Cui L., et al. DNA microarray-based identification of genes associated with glycopeptide resistance in Staphylococcus aureus. Antimicrob. Agents Chemother. 49 (2005) 3404-3413
8. McAleese F., et al. Overexpression of genes of the cell wall stimulon in clinical isolates of Staphylococcus aureus exhibiting vancomycin-intermediate- S. aureus-type resistance to vancomycin. J. Bacteriol. 188 (2006) 1120-1133
9. McCallum N., et al. Strain dependence of the cell wall-damage induced stimulon in Staphylococcus aureus. Biochim. Biophys. Acta 1760 (2006) 1475-1481
10. Mwangi M.M., et al. Tracking the in vivo evolution of multidrug resistance in Staphylococcus aureus by whole-genome sequencing. Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 9451-9456
11. Howden B.P., et al. Genomics reveals a point mutation in the two-component sensor gene graS that leads to vancomycin-intermediate resistance in clinical Staphylococcus aureus. Antimicrob. Agents Chemother. 52 (2008) 3755-3762
12. Renzoni A., et al. Identification by genomic and genetic analysis of two new genes playing a key role in intermediate glycopeptide resistance in Staphylococcus aureus. Antimicrob. Agents Chemother. 53 (2009) 903-911
13. Meehl M., et al. Interaction of the GraRS two-component system with the VraFG ABC transporter to support vancomycin-intermediate resistance in Staphylococcus aureus. Antimicrob. Agents Chemother. 51 (2007) 2679-2689
14. Herbert S., et al. Molecular basis of resistance to muramidase and cationic antimicrobial peptide activity of lysozyme in staphylococci. PLoS Pathog. 3 (2007) e102
15. Cui L., et al. Correlation between reduced daptomycin susceptibility and vancomycin resistance in vancomycin-intermediate Staphylococcus aureus. Antimicrob. Agents Chemother. 50 (2006) 1079-1082